Related Experiment Video

Updated: Apr 29, 2026

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

9.2K

The complement system in inflammatory bowel disease

Umang Jain1, Anthony R Otley, Johan Van Limbergen

  • 1*Department of Microbiology and Immunology, †Department of Pediatrics, and ‡Department of Community Health and Epidemiology, Dalhousie University, and the IWK Health Centre, Halifax, NS, Canada.

Inflammatory Bowel Diseases
|May 17, 2014
PubMed

Insights

The complement system, a key immune defense, is increasingly linked to inflammatory bowel disease (IBD) pathogenesis. Research into therapeutic complement inhibition offers new avenues for treating IBD.

Area of Science:

  • Immunology
  • Gastroenterology
  • Innate Immunity

Background:

  • The complement system is a crucial part of innate immunity, defending against microbes and clearing cellular debris.
  • Dysregulation of complement activation is implicated in chronic inflammatory diseases.
  • The role of complement in inflammatory bowel disease (IBD) remains under-researched.

Purpose of the Study:

  • To review the existing evidence on the complement system's role in IBD pathogenesis.
  • To explore the potential for therapeutic manipulation of complement in IBD.

Main Methods:

  • Review of current literature on complement and IBD.
  • Analysis of studies using genetically modified animal models.
  • Examination of research involving complement antagonists.

Main Results:

  • Emerging research implicates the complement system in the development of IBD.
  • Novel experimental approaches are providing critical insights.
  • Therapeutic strategies targeting complement are under investigation.

Conclusions:

  • The complement cascade plays a significant role in IBD.
  • Targeting complement activation presents a promising therapeutic strategy for IBD.
  • Further research is warranted to fully elucidate and exploit complement's role in IBD.

More Related Videos

Chronic Salmonella Infection Induced Intestinal Fibrosis08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

6.7K
Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.2K

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
33
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
10.5K
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
31
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows...
37
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The...
32
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K